id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-6580-9291,FDA,FDA-2017-D-6580,"Drug Products Labeled as Homeopathic; Draft Guidance for Food
and Drug Administration Staff and Industry; Extension of Comment
Period",Notice,Extension of Comment Period,2020-03-16T04:00:00Z,2020,3,2020-03-16T04:00:00Z,2020-05-24T03:59:59Z,2020-03-16T15:58:36Z,2020-05318,0,0,0900006484447d14
FDA-2017-D-6580-5125,FDA,FDA-2017-D-6580,Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry; Extension of Comment Period,Notice,Extension of Comment Period,2020-01-08T05:00:00Z,2020,1,2020-01-08T05:00:00Z,,2020-01-08T14:54:20Z,2020-00091,0,0,090000648427bef7